## Supplementary



Figure S1 Workflow of this study. TMB, tumor mutation burden. TMBPI, TMB prognostic index.



Figure S2 he general information of the mutations in TP53<sup>mut</sup> (A-F) and TP53<sup>wt</sup> (G-L) LUAD. (A-C; G-I) Statistical analysis of somatic mutation types according to category. The bar plots show the cumulative number of variants identified in the samples. (D-E; J-K) Assessment of tumor mutation burden with the number variants per sample. (F; L) The top 10 most frequently mutated genes in the samples. Colored bars represent variant classification. LUAD, lung adenocarcinoma; TP53 mutation; INS, insertion; DEL, deletion.



В SMD3 [56] K11 [39] TA1 [34] RP2 [33] TN [73] RAS [71] UC16 [6] G [30] ZNF536 (27) DNAH9 (27) EGFR [28] COL11A1 [28] NPAP1 [29] NAV3 [30] FLG [30] P < 0.001 CSMD1 [32] P < 0.05 XIRP2 [33] SPTA1 [34] STK11 [39] ZFHX4 [40] USH2A [43] KEAP1 [44] RYR2 [48] >3 (Co-occurence) LRP1B [51] 2 -log10(P-value) CSMD3 [56] 1 MUC16 [67] 0 KRAS [71] TTN (73) 2 > 3 (Mutually exclusive)

**Figure S3** The coincident and exclusive associations across the mutated genes in  $TP53^{\text{mut}}$  (A),  $TP53^{\text{wt}}$ (B) and all (C) LUAD. Green represents co-occurrence and red represents mutually exclusive relationships (\*P<0.001;  $\bullet$ P<0.05). LUAD, lung adenocarcinoma;  $TP53^{\text{mut}}$ , TP53 mutation;  $TP53^{\text{wt}}$ , wild-type TP53.



**Figure S4** Correlation of TMB levels with clinical features. (A, B) Higher TMB levels related significantly to the  $\leq$ 65-year age group (P=0.005) and male gender (P=0.003). (C-F) No significant difference of TMB levels was observed for AJCC-T stage, AJCC-N stage, AJCC-N stage, and AJCC-I~IV stage. Red and green represent the different groups in each box plot. TMB, tumor mutation burden.